Table 4.
Author | Year | Country | Serum Ab | Pos | Total | % | Comments |
---|---|---|---|---|---|---|---|
Gillison [37] | 2000 | US | 34 | 60 | 57 | Most HPV 16. HPV more likely in nonsmokers (7/8) than smokers (27/51) | |
Mellin [38] | 2000 | Sweden | 26 | 60 | 43 | More women in HPV+ group | |
Schwartz [39] | 2001 | US | 18 | 44 | 41 | HPV more common in never smokers 14/42 than ever smokers | |
Mork [40] | 2001 | Scandinavia | Yes | 9 | 18 | 50t | |
Ringstrom [41] | 2002 | US | 15 | 29 | 52 | All HPV16 | |
Dahlstrom [42] | 2003 | US | Yes | 41 | 70 | 59 | HPV16 more common in never smokers (24/35) than ever smokers (17/35) Serum HPV16 L1 Ab predictive for oropharyngeal SCC, OR 59.53 (95% CI: 5.71-620-2) |
El-Mofty [43] | 2003 | US | 10 | 11 | 91 | All tonsil HPV16 | |
Herrero [44] | 2003 | Multiple | Yes | 26 | 142 | 18t | Serum HPV16 E6 or E7Ab predictive for oropharyngeal SCC, OR = 9.2 (95% CI: 4.8–17.7) |
Begum [45] | 2005 | US | 37 | 45 | 82 | ||
Hansson [46] | 2005 | Sweden | 21 | 46 | 46o | HR HPV DNA in oral mouthwash samples predictive for oropharyngeal SCC, OR = 230 (44–1,200) on multivariate regression analysis | |
Ibieta [47] | 2005 | Mexico | 4 | 9 | 44 | Most HPV16, no tonsillar SCC included, only retromolar trigone | |
Koppikar [48] | 2005 | India | 2 | 6 | 33 | Most were HPV16, but 14% were multiple HPV infections, (including HPV18, 8, 38) | |
Kreimer [49] | 2005 | Multiple | Yes | 25 | 141 | 18s | Serum HPV VLP Ab plus high tumor viral load predictive for oropharyngeal SCC, OR 12.0 (95% CI 5.2–27.5) |
Tachezy [50] | 2005 | Czech | 32 | 56 | 57 | HPV more common in never smokers (7/7) than ever smokers 28/61 | |
El-Mofty [51] | 2006 | US | 12 | 20 | 60 | HPV 16 | |
Licitra [52] | 2006 | Italy | 17 | 90 | 19 | All HPV16, 2 SCC integrated only, remaining both episomal and integrated | |
Nemes [53] | 2006 | Hungary | 1 | 8 | 13 | Most HPV16, most integrated HPV more common in never smokers (7/18) than ever smokers 26/61 |
|
Weinberger [54] | 2006 | US | 48 | 79 | 61 | ||
DeSouza [55] | 2007 | US | 72 | 100 | 72 | ||
Furniss [56] | 2007 | US | Yes | 116 | 288 | 40.3s | High HPV16 L1 serum Ab titer predictive for oropharyngeal SCC, OR = 30.3 (95% CI 12.4–73.6) |
Pintos [57] | 2007 | Canada | Yes | 9 | 17 | 53s | Serum HPV16 VLP predictive for oropharyngeal SCC, OR = 27.68 (95% CI 7.5–102.2) by crude analysis |
Smith [58] | 2007 | US | Yes | 35 | 62 | 56s | Serum HPV16 E6/E7Ab predictive for oropharyngeal SCC, OR = 72.8 (95% CI 16.0–330) |
Schlecht [59] | 2007 | US | 7 | 17 | 41 | Most HPV16 |
OR overall risk; Ab serum antibodies; HR high-risk; s seropositivity results; t tumor results; o oral mouthwash results; VLP viral like particles; CI confidence intervals